- Home
- CHW vs HRTX Comparison
CHW vs HRTX Comparison
Compare CHW & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHW
- HRTX
- Stock Information
- Founded
- CHW 2007
- HRTX 1983
- Country
- CHW United States
- HRTX United States
- Employees
- CHW N/A
- HRTX N/A
- Industry
- CHW Investment Managers
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- CHW Finance
- HRTX Health Care
- Exchange
- CHW Nasdaq
- HRTX Nasdaq
- Market Cap
- CHW 453.1M
- HRTX 317.0M
- IPO Year
- CHW N/A
- HRTX 1987
- Fundamental
- Price
- CHW $7.20
- HRTX $1.82
- Analyst Decision
- CHW
- HRTX Strong Buy
- Analyst Count
- CHW 0
- HRTX 3
- Target Price
- CHW N/A
- HRTX $6.00
- AVG Volume (30 Days)
- CHW 195.2K
- HRTX 1.8M
- Earning Date
- CHW 01-01-0001
- HRTX 11-12-2024
- Dividend Yield
- CHW 9.27%
- HRTX N/A
- EPS Growth
- CHW N/A
- HRTX N/A
- EPS
- CHW N/A
- HRTX N/A
- Revenue
- CHW N/A
- HRTX $136,361,000.00
- Revenue This Year
- CHW N/A
- HRTX $18.46
- Revenue Next Year
- CHW N/A
- HRTX $21.59
- P/E Ratio
- CHW N/A
- HRTX N/A
- Revenue Growth
- CHW N/A
- HRTX 15.60
- 52 Week Low
- CHW $5.07
- HRTX $0.50
- 52 Week High
- CHW $6.54
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- CHW 54.78
- HRTX 41.85
- Support Level
- CHW $7.15
- HRTX $1.43
- Resistance Level
- CHW $7.35
- HRTX $1.93
- Average True Range (ATR)
- CHW 0.10
- HRTX 0.13
- MACD
- CHW -0.00
- HRTX -0.01
- Stochastic Oscillator
- CHW 50.00
- HRTX 54.17
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment strategy is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.